Now the CFO Joins In. Same $18 Level.
The CEO's $1.5 million check hit earlier today, and now the CFO is writing $499,986 at the same $18 mark. That's the two most important seats at the table buying the same clinical-stage cardio name in the same session, and it stacks on top of a cluster that already had six insiders in over the past 30 days. This company didn't exist before 2024, so there's no price history to lean on and no chart to confirm anything. The insider signal is all you've got here, but when the CEO and CFO both step in at once, that's the strongest version of the signal there is.
The Filing
| Ticker | BRVE |
| Company | Braveheart Bio, Inc. |
| Insider | James Paul Rickey, Chief Financial Officer |
| Buy amount | $499,986 |
| Filing date | August 7, 2026 |
| Conviction | Interesting · 60/100 |
| Setup type | Insufficient Data |
Ultimate members received this analysis in real time.